What's the recommended frequency for lurbinectedin's side effect surveillance?

For lurbinectedin, the recommended side-effect (safety) surveillance frequency isn’t one single universal interval for every patient—it depends on the phase of therapy, your local protocol, and the specific adverse effects being watched for. That said, typical practice and label/clinical-monitoring standards generally follow this pattern:

• Before each dose (baseline for that cycle): review symptoms and do relevant labs (commonly CBC with differential and liver function tests—AST/ALT, bilirubin—because cytopenias and transaminitis are key risks).
• Ongoing during each cycle: additional checks if abnormalities are present or if symptoms suggest complications—especially for neutropenia/febrile neutropenia (may require more frequent CBCs) and liver enzyme elevations (may require more frequent LFTs).
• After dose modifications/interruptions: surveillance generally increases (more frequent labs and closer follow-up) until the abnormality resolves or returns to acceptable thresholds.

If you want the exact interval

I can give the precise “frequency” you’re looking for, but I need one detail:

1. Are you asking about routine monitoring per prescribing information (label-based), or how often to check labs during a cycle in a specific setting (e.g., oncology clinic protocol)?
2. Which regimen/indication (e.g., lung cancer monotherapy or combination) and whether you mean pre-dose vs mid-cycle vs post-dose?

If you tell me the country/label you’re using (FDA/EMA) and the trial/regimen, I’ll map it to the exact monitoring schedule.